This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogène
This Kallikrein 2 (KLK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-197 amino acids from the C-terminal region of human Kallikrein 2 (KLK2).
KLK2
Reactivité: Humain
WB, IP
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
For WB starting dilution is: 1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
Kallikrein 2 (KLK2)
Autre désignation
Kallikrein 2
Sujet
Kallikreins are a group of serine proteases manifesting diverse physiological functions. The glandular kallikreins are a distinct group of serine proteases with an ability to release vasoactive peptides from kininogen in vitro, although the kininogenase activity of different kallikreins is highly variable. Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. Many kallikrein genes are differentially expressed in various malignancies. Human glandular kallikrein (hK2, encoded by the KLK2 gene) is an emerging tumor marker for prostate cancer.